| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.29 | 3e-09 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.27 | 3e-08 |
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | 0.18 | 7e-07 |
| mRNA | barasertib | CTRPv2 | pan-cancer | AAC | 0.16 | 5e-06 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.17 | 8e-06 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | 0.17 | 2e-05 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | 0.16 | 2e-05 |
| mRNA | AT-7519 | GDSC1000 | pan-cancer | AAC | 0.14 | 3e-05 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.15 | 5e-05 |
| mRNA | KIN001-102 | GDSC1000 | pan-cancer | AAC | 0.13 | 6e-05 |